Government

Five things for pharma marketers to know: Tuesday, January 24, 2017

Five things for pharma marketers to know: Tuesday, January 24, 2017

By

Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role

Five things for pharma marketers to know: Friday, January 20, 2017

Five things for pharma marketers to know: Friday, January 20, 2017

By

Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

By

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

By

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Five things for pharma marketers to know: Tuesday, December 13, 2016

Five things for pharma marketers to know: Tuesday, December 13, 2016

By

Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

By

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

Five things for pharma marketers to know: Thursday, June 16, 2016

By

A government watchdog criticizes the FDA; the FDA strengthens kidney warnings for Invokana and Farxiga; people with diabetes are living longer

Biogen under investigation for patient-assistance programs

Biogen under investigation for patient-assistance programs

By

The drugmaker disclosed in its first-quarter earnings report that it is being investigated over ties to nonprofit foundations.

Ascension Health rolls out first ad campaign for VA

Ascension Health rolls out first ad campaign for VA

The Catholic health system worked with FleishmanHillard and GSD&M to create the integrated campaign touting its partnership with the Department of Veterans Affairs.

Five things for pharma marketers to know: Wednesday, December 23, 2015

Five things for pharma marketers to know: Wednesday, December 23, 2015

By

Clinton calls for Alzheimer's funding; an FDA approval of an older drug may mean higher prices; the FDA approves AstraZeneca's gout drug

Obama gives details on Precision Medicine Initiative

Obama gives details on Precision Medicine Initiative

By

President Barack Obama's recently unveiled Precision Medicine Initiative hopes to develop a new model of patient-driven research with the promise of accelerating biomedical discoveries and provide clinicians with new tools, knowledge, and therapies.

Business briefs: AbbVie, FDA, and health spending projections

AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011

US awards GSK $200M to fight "superbugs"

By

GSK and the US Department of Health and Human Services inked a deal to fund development of new antibiotics, an area where clinicians face a dearth of new options.

It's Consumer's Choices as Guidelines Change

It's Consumer's Choices as Guidelines Change

Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.

Obama budget would bleed pharmas

By

The White House released its proposed budget for the 2014 fiscal year this morning, and while it gives a modest boost to Health and Human Services, it also seeks to extract more cost savings from pharmas.

For Obama's head-less CMS, third time's the charm

For Obama's head-less CMS, third time's the charm

By

Acting administrator Marilyn Tavenner seems on track for confirmation, with the blessings of all industry stakeholders

Success in emerging markets hinges on broad network

By

Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.

Court could punt "Pay for Delay" back to Congress

By

Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called "pay for delay" settlements hangs in the balance.

Senate vote puts ACA's device tax in doubt

Senate vote puts ACA's device tax in doubt

By

In a big win for the device industry, Senators voted overwhelmingly on a symbolic— but politically potent—motion to scrap the 2.3% device excise tax.

Sequester cuts could snarl approvals for years

Sequester cuts could snarl approvals for years

By

With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it's certain the approvals process will slow as the agency absorbs the loss.

CMS warms to some stakeholders, burns others with Sunshine rule

By

Clinical Research Organizations, marketing research firms, accredited CME providers and lawyers look to be the big winners in CMS's Sunshine Act rule.

CMS releases "Sunshine" final rule: federal preemption, August start date

CMS releases "Sunshine" final rule: federal preemption, August start date

By

CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.

Congress spares pharmas from going over another cliff—for now

Congress spares pharmas from going over another cliff—for now

By

For the drug industry, the big news in the "fiscal cliff" deal is that the next big congressional showdown—one that could have big implications for the healthcare industries—has been kicked down the road a couple months.

Congress loses a healthcare mover, and pharma an unlikely ally on IPAB

Congress loses a healthcare mover, and pharma an unlikely ally on IPAB

By

The November elections were arguably the most important for healthcare policy in 40 years, cementing, as they did, the Affordable Care Act by awarding President Obama a second term. But with all eyes glued to the drama at the top of the ticket, many missed a major Congressional upset that could have big implications for healthcare policy.

Amgen pleads guilty, takes CIA in $762 million False Claims Act case

Amgen pleads guilty, takes CIA in $762 million False Claims Act case

By

Amgen "marketed the spread" between the price practices pay for Aranesp and that patients pay as a means of driving sales—to the point of having speakers tell docs that they could make a million more each year by prescribing the Amgen anemia drug over its competitor, Procrit.

FDA regulatory policy chief to take on compounding question

FDA regulatory policy chief to take on compounding question

By

FDA's Jane Axelrad is leaving the Office of Regulatory Policy to head the agency's compounding policy rethink.

CBO: more scripts filled, less healthcare spending

By

The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.

Congressmen spar over meningitis blame

By

Members of the House Energy and Commerce committee alternatively blamed and excused the FDA over the meningitis outbreak that has killed 32 patients.

Full steam ahead for Obamacare, but gridlock isn't going anywhere

Full steam ahead for Obamacare, but gridlock isn't going anywhere

By

President Obama has cemented his greatest legislative achievement, the Affordable Care Act, but the status quo should prove anything but boring, with implementation of the law sure to mean more political fireworks

Voting with their wallets, pharmas say no thanks to change

Voting with their wallets, pharmas say no thanks to change

By

Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters